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a b s t r a c t
Antibodies have widespread applications in areas ranging from therapeutics to chromatography and
protein microarrays. Certain applications require only the fragment antigen-binding (Fab) units of the
protein. This study compares the cleavage efﬁcacy of dithiothreitol (DTT), mercaptoethylamine (MEA),
and dithiobutylamine (DTBA) – a relatively new reducing agent synthesized in 2012. Pseudo-ﬁrst order
kinetic analyses show DTBA to be 213 times faster than DTT and 71 times faster than MEA in the
formation of Fab' antibody fragments from polyclonal rabbit antibodies. Monoclonal mouse antibodies
were also used to show the feasibility of the reduction process on antibodies from a different species and
with a different clonality. DTBA cleaved the monoclonal mouse F(ab)2 units most efﬁciently, 2 times
faster than DTT 10 times faster than MEA. Due to the extremely quick reactivity of all the reducing
agents in the ﬁrst ﬁve minutes of monoclonal antibody reductions as well as for the DTBA reductions of
the polyclonal rabbit antibodies, the pseudo-ﬁrst order kinetic analyses should be interpreted
qualitatively for these results. Nucleophilic sulﬁdes on Fab' fragments are preserved in the DTBA
reduction process, demonstrated by their reactivity with Ellman's reagent. Degradation of the Fab'
fragments was observed with the monoclonal mouse antibodies after reduction with DTBA or DTT. In
conclusion, DTBA is the more efﬁcient reducing agent compared to DTT and MEA, however, the reduction
process should be optimized as degradation of the Fab' fragments is possible.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Immunoglobulins, or antibodies, are large proteins produced by
the immune system that have found numerous applications in
many different ﬁelds. Some examples include the use of these
proteins in therapeutics, immunoafﬁnity capillary electrophoresis,
immunoafﬁnity chromatography, protein microarray technology,
and immunosensors [1–5]. Certain applications require the use of
only speciﬁc parts of the antibody, such as the F(ab)2, Fab, or Fc
fragments (Fig. 1) [6–16].
One of the most commonly encountered classes of antibodies is
the immunoglobulin G (IgG). The structure of a general IgG
antibody contains four protein chains – two pairs of two chains,
with each pair consisting of a heavy and light chain [17,18]. The
portion of the antibody that binds to speciﬁc antigens is called the
fragment–antigen binding (Fab) unit. Each antibody contains two
Fab fragments and one tail Fc fragment (Fig. 1). The proline and
cysteine-rich hinge region contains key disulﬁde bridges that hold
the two halves of the antibody together [17,18]. This region lies
exposed between the heavy chain constant variable domains CH1
and CH2, making it susceptible for enzymatic attack [17].
A common approach for the fragmentation of antibodies is
through the use of proteolytic enzymes [19–23]. Papain, pepsin,
bromelain, ﬁcin, lysyl endopeptidase are frequently used enzymes,
with the ﬁrst two being the most popular. Antibody cleavage with
papain results in the formation of two Fab fragments and one Fc
fragment [19,22,23]. This enzyme cleaves the antibody above the two
key hinge disulﬁde bridges (Fig. 1). Alternatively, pepsin cleaves the
antibody below the two disulﬁde bridges, resulting in an F(ab)2
fragment and an Fc fragment [20–23]. The F(ab)2 fragment may then
be reduced to yield two Fab' fragments with C-terminal nucleophilic
sulﬁdes [6–16]. Pepsin may also be immobilized onto a resin instead
of dissolved in solution [2]. This allows for the reaction to be stopped
immediately through the quick removal of the resin from solution.
However, antibody cleavage using either papain or pepsin must be
optimized for each antibody class and subtype [21–23]. For example,
mouse IgG1 cannot be cleaved using pepsin whereas mouse IgG2a
and IgG2b are very reactive towards pepsin [21]. Although pepsin has
an optimum cleavage efﬁciency in very acidic solutions (pH¼2.0),
antibody denaturation and diminished antigen-binding ability are
also associated with such harsh conditions [23]. As a result, less
acidic (pH¼3–4) solutions are used during pepsin antibody cleavage.
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The reduction of F(ab)2 dimers, formed from the pepsin cleavage,
yields Fab' fragments containing nucleophilic sulﬁdes that can be
used successfully for immobilization onto surfaces [6–16]. Some
commonly encountered reducing agents are β-mercaptoethanol (β-
ME), tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT),
and mercaptoethylamine (MEA) [24–29]. The formation of Fab'
fragments from F(ab)2 involves the initial rate-limiting nucleophilic
attack of the reducing agent on a hinge disulﬁde bond [27]. After
the steps for thiol-disulﬁde interchange are completed, Fab' frag-
ments are released. Monothiol reducing agents, such as β-ME, have
been shown to “adhere” to the molecules that they are reducing and
are not preferred for F(ab)2 cleavage [24]. Phosphine-based redu-
cing agents, such as TCEP, offer the beneﬁt of yielding irreversible
reactions, driven by the formation of trialkylphosphine oxides. TCEP
is also air-stable, reacts rapidly, and can be used in dilute conditions
[26]. Although more efﬁcient than DTT at cleaving small molecule
disulﬁdes, TCEP has signiﬁcant limitations with large peptides due
to steric crowding from the 2-carboxyethyl arms [24,29]. Currently,
the two most common reducing agents for the formation of Fab'
fragments are DTT and MEA. As a dithiol, DTT offers the beneﬁt of
performing an intramolecular attack of the disulﬁde once the ﬁrst
thiol has attached to the molecule being reduced. The resulting
oxidized DTT product is a cyclic disulﬁde that is thermodynamically
favorable due to its steric speciﬁcations [25]. This intramolecular
step is roughly 103–104 faster compared to its intermolecular
counterpart [27]. Another beneﬁt of DTT is that it is possible to
monitor the course of the reaction by UV–vis methods through the
formation of the oxidized DTT molecules, which absorb at 310 nm.
MEA, although a monothiol, is able to cleave F(ab)2 dimers without
“sticking” to the molecules [1,2]. Compared to MEA, DTT has shown
to be inconsistent with the cleavage of different antibodies, some-
times cleaving the disulﬁde bonds between the antibody chains [2].
First synthesized in 2012, dithiobutylamine (DTBA) is a new
dithiol reducing agent, similar in structure to both DTT and MEA
[24,30]. Due to its novelty, it has had limited application and has
not been used yet, to our knowledge, in the ﬁeld of antibody-based
chemistry. However, DTBA has desirable characteristics since its
hydrochloride salt is nearly odorless and is highly soluble in water
[24]. Having lower pKa values allows for DTBA to have more
nucleophilic deprotonated sulﬁdes present at any given pH com-
pared to DTT and MEA (Fig. 2). The lower pKa values are believed
to be a result of strong Coulombic and inductive effects from the
amino group, similar to what is observed with MEA [24]. The
amino group of DTBA may also be used to immobilize DTBA to
resins. Immobilized DTBA has been used in reducing cystines of
large enzymes, although it has diminished cleaving ability com-
pared to DTBA molecules free in solution [30].
In this study, the reduction efﬁcacies of DTT, MEA, and DTBA are
kinetically compared with respects to the cleavage of polyclonal rabbit
IgG F(ab)2 fragments. The three reducing agents are compared at room
temperature (22 1C) and physiological temperature (37 1C). Reductions
with DTBA are also compared using varying concentrations of the
reducing agent at room temperature. Reduced solutions are analyzed
quantitatively using size-exclusion chromatography and UV–vis spec-
troscopy and qualitatively with sodium dodecyl sulfate (SDS) poly-
acrylamide gel electrophoresis (PAGE). The Fab' fragments are reacted
with Ellman's reagent to determine the preservation of the C-terminal
nucleophilic sulﬁdes [27,31,32]. In order to test the feasibility of
cleaving antibodies from other species and with differing clonalities,
monoclonal mouse anti-human IgG1 antibodies were also examined.
By virtue of developing reaction conditions for the kinetic study of the
three reducing agents, a new protocol for cleaving antibodies using
DTBA was created.
2. Materials and methods
2.1. Materials
Polyclonal rabbit anti-goat IgG antibodies (G5518) and monoclo-
nal mouse anti-human IgG1 antibodies (I2513) were purchased from
Sigma and used without further puriﬁcation. Pepsin from porcine
gastric mucosa, MEA, DTT, and DTBA were also purchased from
Sigma. Slide-A-Lyzer dialysis cassettes (2000 Da MWCO) were
obtained from Thermo Scientiﬁc. BenchMark Protein Ladder was
received from Life Technologies. Acrylamide, bisacrylamide, glycine,
sodium dodecyl sulfate (SDS), methanol, glacial acetic acid, Coomas-
sie blue, bromophenol blue, glycerol, iodoacetamide, 5–5'-dithiobis
(2-nitrobenzoic acid) (Ellman's reagent), sodium acetate, Trizma base,
ethylenediaminetetraacetic acid (EDTA), sodium chloride, sodium
citrate tribasic dehydrate, sodium phosphate dibasic, and sodium
tetraborate decahydrate were purchased from Sigma and used
without further puriﬁcation. Deionized water, 18.2 Ω, was obtained
from a Milli-Q integral water puriﬁcation system. UV–vis analyses
were performed on an Agilent Cary 60 UV–vis spectrophotometer
operating with a xenon lamp. HPLC puriﬁcation was performed at St.
Michael's Hospital (Toronto, Canada), using two in-line Agilent
ZORBAX Bio Series GF-250 size exclusion columns and a UV–vis
detector. Columns measured 250 mm in length, with an internal
diameter of 4.6 mm. The columns were packed with 4 mm spherical
silica having a pore size of 150 Å. The separations were performed at
room temperature with 0.5 mL/min ﬂow rates and 100 mL injection
volumes using PBS (100 mM sodium phosphate dibasic, pH 7.0)
Fig. 1. Cleavage scheme for a general IgG antibody using either papain or pepsin and a reducing agent.
Fig. 2. Structures and pKas of DTBA, DTT, and MEA [24].
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mobile phase. The peaks were monitored at 280 nm wavelengths
using yeast (150 kDa), albumin (66 kDa), carbonic anhydrase
(29 kDa), and cytochrome C (12 kDa) calibration standards (2.5 mg/
mL each).
2.2. SDS-PAGE analyses
All samples for SDS-PAGE were prepared in non-reducing con-
ditions. The analyses were cast using 12% SDS-PAGE gels from a 40%
acrylamide solution (36:1 acrylamide:bisacrylamide mass ratio).
Samples were run at constant voltage (220 V) using Laemmli
running buffer. The non-reducing loading buffer, containing
11.5% (v/v) 1.0 M Trizma pH 8.8 buffer, 3.7% (w/v) SDS, 27.5% (v/v)
glycerol, and 0.018% (w/v) bromophenol blue, was prepared in
distilled water. The Benchmark Protein Ladder (10–190 kDa) was
used for molecular weight sizing. A 0.05% (w/v) Coomassie blue
stain containing 40% (v/v) methanol and 10% (v/v) glacial acetic acid
was used to stain the gels. To destain the gels, a solution containing
40% (v/v) methanol and 10% (v/v) glacial acetic acid in distilled
water was used.
2.3. Optimization of whole antibody to F(ab)2 cleavage
Enzymatic digestion of polyclonal anti-goat IgG and monoclonal
anti-human IgG1 using pepsin was tested with both phosphate-
buffered saline (PBS) (10 mM sodium phosphate dibasic, 154 mM
sodium chloride) and acetate (100 mM sodium acetate) buffers at pH
4.0 and 4.5. The following incubation incubation times were tested
for each buffer and pH combination: 1, 2, 3, 4, 6, 8, 24, and 48 h. A
1 mg/mL antibody sample was partitioned into four solutions (pH
4.0 acetate buffer, pH 4.5 acetate buffer, pH 4.0 PBS buffer, pH 4.5 PBS
buffer), with each of the four solutions being subdivided into 16
equal portions. For each set of 16 portions, half were used with
pepsin treatment and the other half were used as controls with only
buffer added. The added pepsin solution was made from the same
buffer and pH combination as the solution that it was being added
into. Pepsin was used in a 1:40 pepsin:antibody mass ratio in order
to minimize potential damage of the antibody binding site by pepsin.
The solutions with added pepsin were incubated at 37 1C for the
different time lengths stated earlier. The reactions were stopped with
the addition of 2 M Trizma base solution to yield a solution with
pH¼8.0. Aliquots from each reaction were then prepared in the SDS-
PAGE loading dyes and analyzed using SDS-PAGE.
2.4. Kinetic analyses of F(ab)2 reduction
Anti-goat IgG (1 mg/mL) or anti-human IgG1 (4 mg/mL) was
dialyzed overnight in Slide-A-Lyzer dialysis cassettes against pH
4.0 acetate buffer (deionized water, 100 mM sodium acetate). The
concentration of the antibody solution was determined using UV–
vis analysis at 280 nm following dialysis. To generate F(ab)2
fragments, pepsin solution (0.1 mg/mL pepsin in 100 mM sodium
acetate buffer, pH 4.0) was added in a mass ratio of 1:40 enzyme:
antibody. The resulting solution was incubated at 37 1C for 24 h.
The reaction was quenched with 2 M Trizma base solution to yield
a solution with pH¼8.0. The treated digest was dialyzed overnight
against a preparative pH 5.5 reduction buffer (deionized water,
3 mM EDTA, 100 mM sodium chloride, 50 mM sodium citrate
tribasic dehydrate, 100 mM sodium tetratborate decahydrate).
The concentration of the antibody solution was determined using
UV–vis following dialysis.
Antibodies were cleaved in four different experiments, with
each experiment performed in triplicate. The ﬁrst experiment
compared the three reducing agents (DTT, MEA, DTBA) at room
temperature (22 1C) against polyclonal anti-goat IgG antibodies.
The reducing agents were added to the F(ab)2 solutions at a ratio
of 2 mM reducing agent to 1 mg/mL F(ab)2. Aliquots of 100 mL and
2 mL were retrieved for future HPLC and SDS-PAGE analyses at the
following time points: 5, 10, 20, 40, 90, 180, 300, and 480 min.
HPLC aliquots were frozen immediately using liquid nitrogen and
stored at -30 1C. SDS-PAGE samples were quenched with a 10-fold
excess of iodoacetamide and allowed to react for 30 min before
being stored at -30 1C. The second experiment varied three
concentrations of reducing agent – 0.5 mM, 1 mM, and 2 mM
DTBA to 1 mg/mL of polyclonal anti-goat IgG F(ab)2 – using the
same protocol as described above. The third experiment assessed
reducing capabilities of DTT, MEA, and DTBA at physiological
temperature (37 1C) using the same procedure with the concen-
trations held at 2 mM reducing agent to 1 mg/mL of polyclonal
anti-goat IgG F(ab)2. It should be noted that the experiments at
physiological temperature were stopped after the 90 min time
point. The ﬁnal experiment examined the feasibility of cleavage
using monoclonal mouse anti-human IgG1 antibodies at room
temperature (22 1C). The concentrations of the reducing agents
were held at 2 mM reducing agent to 1 mg/mL of monoclonal anti-
human IgG1 antibodies.
HPLC analyses were performed shortly after reduction and
samples were thawed individually just before each run. Internal
standards containing known concentrations of F(ab)2 and Fab'
fragments were used to allow quantitative analysis of each sample.
Samples for SDS-PAGE analyses were thawed, mixed with loading
dyes, and ran on 12% SDS-PAGE gels.
2.5. Ellman's test for Fab' nucleophilic sulﬁdes
Fab' fragments generated from the HPLC separation of the
samples were reacted with Ellman's reagent. Aliquots of 1 mL
containing known amounts of Fab fragments were diluted to 3 mL
in pH 7.4 phosphate buffer (100 mM sodium phosphate dibasic,
1 mM EDTA). Ellman's reagent (10-fold molar excess) was added
and the resulting solutions were monitored in a 1-cm UV cell at
25 1C for 15 min. The formation of 2-nitro-5-thio-benzoic acid was
quantitatively determined at 412 nm using an extinction coefﬁ-
cient of 14,150 M1 [27,31,32].
3. Results and discussion
3.1. Optimization of the cleavage protocols
Polyclonal rabbit IgG antibodies were chosen for this study as
they have been shown to be a good model for the prediction of
general antibody behavior, which may be extended to antibodies
from other species [8,33,34]. However, it was also important to
show the varying effects of the reducing agents on antibodies from
different species and with differing clonalities. Thus, monoclonal
mouse anti-human IgG1 antibodies were also tested against the
reducing agents. For both antibodies, the optimization of pepsin
cleavage yielded the best results when pepsin was used in pH
4.0 acetate buffer over 24 h. SDS-PAGE analyses indicated that this
time, buffer, and pH combination produced no undesirable clea-
vage byproducts while maximizing the amount of F(ab)2 gener-
ated for the polyclonal rabbit anti-goat IgG antibodies. The
monoclonal mouse anti-human IgG1 antibodies were more resi-
lient to the pepsin cleavage and very little cleavage occurred
before the 24 h mark. After 48 h, there was no apparent F(ab)2
molecules left in solution, indicating undesirable degradation by
pepsin. An additional test showing pepsin cleavage at 24, 28, 32,
36, 40, 44, and 48 h also showed that the maximum amount of F
(ab)2 was obtained at the 24 h point for the monoclonal anti-
human IgG1 antibodies. It should be noted that undesirable
byproducts were observed in all of the time points and complete
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whole antibody cleavage was not achieved in any of the time
points for the monoclonal antibodies.
The reduction buffer conditions were chosen based on previous
studies by Jiskoot in 1990 and Zheng in 2006 [35,36]. Antibodies
have been found to precipitate at strongly acidic solutions (pH¼3.0)
and to decompose in alkaline conditions [35]. Thus, it was necessary
to chose a reduction buffer that was able to maintain the ionic
strength required for proper antibody conformation as well as a pH
that the antibodies could tolerate. Deamidation is a common
degradation pathway for antibodies and can be minimized using
appropriate buffer constituents. Zheng showed more prominent
antibody deamidation in both citrate and phosphate buffers at
neutral pH. However, at using citrate buffers at pH 5.5, deamidation
was minimized [36]. Another common problem that can result in
loss of biological activity is protein aggregation, which is inﬂuenced
by temperature, ionic strength, and time in solution. It has been
shown that citrate buffers, particularly those at pH 5.5, exhibit less
protein aggregation compared to phosphate buffers [36].
3.2. Kinetic comparisons of DTT, MEA, and DTBA
The results of the kinetic analyses following the reduction of F
(ab)2 units to Fab' fragments are shown in Figs. 3–5. Comparison of
the kinetic rate constants of DTT, MEA, and DTBA at room tempera-
ture (22 1C) for the polyclonal anti-goat IgG antibodies yields ratios of
kDTBA/kDTTE213, kDTBA/kMEAE71, and kMEA/kDTTE3. These ratios
indicate kinetic superiority of DTBA in the reduction of F(ab)2
fragments at room temperature. The reduction process was nearly
complete in 3 h time using DTBA, whereas both DTT and MEA were
far from completion (Fig. 3A). These quantitative results are con-
ﬁrmed using qualitative SDS-PAGE analyses. The SDS-PAGE results
(Supporting Information), show a decrease in the intensity of the F
(ab)2 band around 110 kDa and an increase in the intensity of the Fab'
fragment band around 55 kDa. The changes in the two bands are
most noticeable in for the 90, 180, and 300 min time points. In these
time points, the F(ab)2 band intensity drops off signiﬁcantly with a
sudden increase in Fab' band intensity for DTBA reductions. This
trend is not observed for the DTT and MEA SDS-PAGE analyses,
conﬁrming the kinetic results. There is an increase in the band
intensity of the band located near the 26 kDa marker on the SDS-
PAGE for the DTT reduction (Fig. S2). This increase in intensity can be
attributed to the cleavage of the interchain disulﬁdes between the
light and heavy chains of the antibody. This undesirable cleavage is
not observed with the DTBA reduction of the polyclonal antibodies,
conﬁrmed by both HPLC and SDS-PAGE results.
The relatively small difference in the rate constants between
DTT and MEA agree with the observation that both reducing
agents are commonly used for the cleavage of F(ab)2 fragments
[1–20]. It should be noted that due to the extremely fast reducing
capability of DTBA in the ﬁrst 5 min of cleavage, the rate constant
cannot be reliably quantiﬁed with the method used in this study
and should be interpreted qualitatively with respects to the rate
constants of DTT and MEA. These observations should be kept in
mind for all three experiments involving DTBA reduction of
polyclonal anti-goat IgG antibodies.
The results from the cleavage of F(ab)2 fragments at physiolo-
gical temperature (Fig. 3B) show an interesting change in the
relative rates between DTT, MEA, and DTBA. Rate constant ana-
lyses (Supporting Information) yield ratios of kDTBA/kDTTE15,
kDTBA/kMEAE9, and kMEA/kDTTE2. The difference between rate
constants for DTBA at room temperature and physiological tem-
perature did not signiﬁcantly change, whereas the differences
were increased for DTT and MEA. DTBA is still the more efﬁcient
reducing agent at physiological temperature, however, not by as
large of a difference as is observed at room temperature.
Kinetic rate constant comparisons for three varying concentra-
tions of DTBA at room temperature (Fig. 4A) produce rate constant
ratios of k2.0 mM DTBA/k1.0 mM DTBAE3, k2.0 mM DTBA/k0.5 mM
DTBAE40, k1.0 mM DTBA/k0.5 mM DTBAE13. As is expected with a
pseudo-ﬁrst order reaction, an increase in the concentration of
DTBA results in an increase in the rate of the reaction. Compar-
isons of the rate constants for the varying concentrations of DTBA
with the rate constants determined for DTT and MEA at room
temperature (Fig. 3A) give ratios of k1.0 mM DTBA/kDTTE67, k0.5 mM
DTBA/kDTTE5, k1.0 mM DTBA/kMEAE22, and k0.5 mM DTBA/kMEAE2. All
of the tested concentrations of DTBA proved to cleave F(ab)2
fragments faster than the 2.0 mM DTT or 2.0 mM MEA concentra-
tions indicating the kinetic superiority of DTBA with polyclonal
anti-goat IgG antibodies.
The reduction kinetics for the monoclonal anti-human IgG1
antibodies (Fig. 5A) shows all of the reducing agents to work
extremely quickly in the ﬁrst 5 min of the experiment. Due to this,
the calculated pseudo-ﬁrst order rate constants should be inter-
preted qualitatively through relative comparison. Comparing the
ratios of rate constants shows that kDTBA/kDTTE2, kDTBA/kMEAE10,
and kDTT/kMEAE5. Reduction of the F(ab)2 with DTBA and DTT is
complete at the 90 and 180 min time points, as conﬁrmed with the
SDS-PAGE results. Cleavage of the F(ab)2 with MEA was signiﬁ-
cantly slower than with the other reducing agents and appeared to
have slowed down drastically after the ﬁrst ﬁve minutes. The
polyclonal rabbit anti-goat IgG antibodies typically have only one
disulﬁde linkage in their hinge region, whereas it is common to
ﬁnd more than two for monoclonal mouse antibodies [37]. These
results show that DTBA and DTT are able to cleave through the
tougher hinge region of the mouse antibodies, whereas MEA has a
much more difﬁcult time.
It is important to correlate the degradation of the F(ab)2 for both
the polyclonal andmonoclonal antibodies with the formation of their
respective Fab' fragments. Cleavage of the polyclonal F(ab)2 with DTT,
DTBA, and MEA showed an increase in SDS-PAGE band intensity for
the Fab' band as the experiment progressed. The increase in Fab'
fragment concentration was conﬁrmed by HPLC analyses.
Fig. 3. Reduction of polyclonal anti-goat IgG F(ab)2 at (A) room temperature (22 1C) and (B) physiological temperature (37 1C).
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This result was similar with the SDS-PAGE band intensities of
the monoclonal F(ab)2 reductions with DTT and DTBA. However,
very little increase in Fab' band intensity was observed for the
reduction with MEA. As determined with the HPLC analyses, the
concentration of the monoclonal Fab' fragments (Fig. 5B) increased
signiﬁcantly during the DTT and DTBA reductions. The HPLC
analyses indicated a decrease in Fab' fragment concentrations for
these two reductions after the 180 min time point. This may have
started prior to that time, yet it was not noticed in the HPLC
analyses as the rate of Fab' fragment formation was greater than
the rate of Fab' fragment degradation until after the 180 min time
point. This result is strengthened by the increase of the 26 kDa
band intensity of the SDS-PAGE analyses prior to the 180 min time
point. Most likely, DTT and DTBA were participating in interchain
disulﬁde cleavages, resulting in an increase in the concentration of
the light chains in solution. These ﬁndings show that it is crucial to
optimize antibody cleavage in order to maximize on the desired
Fab' fragments and minimize on undesirable cleavages.
With the production of Fab' fragments conﬁrmed, it was neces-
sary to determine whether or not DTBA preserved the nucleophilic
C-terminal sulﬁdes on the fragments. Isolated Fab' fragments from
DTT, MEA, and DTBA cleavages of both polyclonal and monoclonal
antibodies were subjected to Ellman's reagent [27,31,32]. There was
no signiﬁcant difference in the number of nucleophilic sulﬁdes per
Fab' fragment when the products from DTT, MEA, and DTBA
cleavages were compared. The Fab' fragments produced by all the
reducing agents were found to have between 0.90 and 0.94 nucleo-
philic sulﬁdes per Fab' fragment. This result is similar to that
observed with the Fab' fragments obtained after the monoclonal
antibody reductions. The monoclonal Fab' fragments were found to
have between 3.66 and 3.82 nucleophilic sulﬁdes per Fab' fragment.
In conclusion, the F(ab)2 reduction experiments conducted in this
study have shown DTBA to be the more efﬁcient reducing agent
compared to DTT and MEA. The high reduction capabilities observed
by DTBA in the ﬁrst 5 min of the experiment do not allow for reliably
quantiﬁable rate constants. Thus, the rate constant analyses should
be interpreted qualitatively through the relative comparison of the
values. With the cleavage of polyclonal rabbit anti-goat IgG F(ab)2,
DTBA was 213 times faster than DTT and 71 times faster than
MEA. This trend was observed with the cleavage of the monoclonal
mouse anti-human IgG1 F(ab)2 as DTBA was 2 times faster than
DTT and 10 times faster than MEA. Due to the increased number of
hinge disulﬁdes in the monoclonal F(ab)2, difﬁculties with the
cleavage were observed with MEA. No problems were detected with
the DTT and DTBA reductions. However, DTT and DTBA were both
observed to cleave the interchain disulﬁde bonds of the antibody
fragments in the monoclonal antibody reductions. It is very impor-
tant that antibody cleavage is optimized in order to maximize the
yield of the desirable Fab' fragments.
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